Our Advocacy Work

Showing 43–48 of 449 results

Filter By

Clear Filters

  1. Article

    ICER and CFTR Modulators

    The Institute for Clinical and Economic Review (ICER) is assessing the clinical effectiveness and value of CFTR modulators including elexacaftor/tezacaftor/ivacaftor (Trikafta®), tezacaftor/ivacaftor (Symdeko®), lumacaftor/ivacaftor (Orkambi®), and ivacaftor (Kalydeco®). ICER last reviewed CFTR modulators in May 2018.

  2. Download

    ICER Review of CFTR Modulators FAQs


  3. Explainer

    How We Advocate for the CF Community

    Alongside the cystic fibrosis community, we advocate for access to highly specialized CF care, programs, agencies, and policies that help advance research and drug development. We also raise awareness about the disease.

  4. News

    Foundation Shares CF Expertise to Inform ICER Assessment

    December 12, 2017

    The Institute for Clinical and Economic Review (ICER) developed an assessment of the comparative clinical effectiveness and value of cystic fibrosis therapies. The Foundation provided input to help inform this process.

  5. Advocacy News

    Foundation Joins Chronic Disease Organizations to Educate Policymakers on Needs of People with CF

    December 15, 2016

    The Cystic Fibrosis Foundation joined 72 chronic and rare disease organizations to send a letter to President-elect Trump and Congressional leadership.

  6. Press Release

    Fifteen National Patient Advocacy Organizations Urge Congress to Oppose the ACA Repeal

    July 19, 2017

    The organizations called on Congress to take a bipartisan approach to reform.